Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 17/20 | 0.41 |
| ▸ | IDH2 | P48735 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | PDE2A | O00408 | 1/20 | 0.33 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21143856 | 1.00 | IDH1 (0.41) | IDH1IDH2NPC1MAPTRAB9A | |
| SCHEMBL19687542 | 0.87 | IDH1 (0.48) | IDH1IDH2 | |
| SCHEMBL19686291 | 0.82 | IDH1 (0.41) | IDH1IDH2NPC1MAPTRAB9A | |
| SCHEMBL19687073 | 0.82 | IDH1 (0.38) | IDH1NPC1MAPTRAB9AATM | |
| SCHEMBL21144233 | 0.82 | KDM4E (0.37) | IDH1IDH2MAPT | |
| SCHEMBL21166244 | 0.81 | IDH1 (0.37) | IDH1IDH2NPC1MAPTRAB9A | |
| SCHEMBL19687282 | 0.81 | KCNN3 (0.40) | IDH1IDH2MAPTSMN1; SMN2L3MBTL1 | |
| SCHEMBL19686578 | 0.81 | IDH1 (0.51) | IDH1IDH2NPC1MAPTRAB9A | |
| SCHEMBL21166275 | 0.80 | IDH1 (0.42) | IDH1IDH2PDE2AMAPK8 | |
| SCHEMBL19686534 | 0.80 | IDH1 (0.48) | IDH1IDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240317705-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2024-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317705-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | IDH1 3017/4885IDH2 2447/4885NPC1 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.